Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD

被引：0
|
作者：
Laboure, Gaelle
Dulucq, Stephanie [1 ]
Vigouroux, Stephane
Lippert, Eric [1 ]
Pigneux, Arnaud
Tabrizi, Reza
Leguay, Thibaut
Bouabdallah, Krimo
Dilhuydy, Marie-Sarah
Schmitt, Anna
Marit, Gerald
Mahon, Francois-Xavier [2 ]
Milpied, Noel
机构：
[1] CHU Bordeaux, Hematol Lab, Pessac, France
[2] Univ Victor Segalen, Hematol Lab, Pessac, France
来源：
BLOOD | 2011年 / 118卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1766 / 1766
页数：1
相关论文
共 21 条
  • [1] Potent graft-versus-leukaemia effect after reduced-intensity allogeneic stem-cell transplantation as post-remission therapy for intermediate-risk de-novo AML with FLT3-ITD genotype or wild-type (WT) NPM1 and CEBPA without FLT3-ITD
    Laboure, G.
    Vigouroux, S.
    Dulucq, S.
    Labopin, M.
    Lippert, E.
    Pigneux, A.
    Tabrizi, R.
    Leguay, T.
    Bouabdallah, K.
    Dilhuydy, M. S.
    Schmitt, A.
    Marit, G.
    Mahon, F. X.
    Milpied, N.
    BONE MARROW TRANSPLANTATION, 2012, 47 : S417 - S418
  • [2] Potent Graft-versus-Leukemia Effect after Reduced-Intensity Allogeneic SCT for Intermediate-Risk AML with FLT3-ITD or Wild-Type NPMI and CEBPA without FLT3-ITD
    Laboure, Gaelle
    Dulucq, Stephanie
    Labopin, Myriam
    Tabrizi, Reza
    Guerin, Estelle
    Pigneux, Arnaud
    Lafarge, Xavier
    Leguay, Thibaut
    Bouabdallah, Krimo
    Dilhuydy, Marie-Sarah
    Duclos, Cedric
    Lascaux, Axelle
    Marit, Gerald
    Mahon, Francois-Xavier
    Boiron, Jean-Michel
    Milpied, Noel
    Vigouroux, Stephane
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (12) : 1845 - 1850
  • [3] The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations
    Zheng, Wen-shuai
    Hu, Ya-lei
    Guan, Li-xun
    Peng, Bo
    Wang, Shen-yu
    HEMATOLOGY, 2021, 26 (01) : 179 - 185
  • [4] The value of allogeneic stem cell transplantation in patients with intermediate risk (ELN) acute myeloid leukemia with no FLT3-ITD, no NPM1 mutations and no CEBPA double mutations
    Heidrich, K.
    Thiede, C.
    Schaefer-Eckart, K.
    Schmitz, N.
    Aulitzky, W. E.
    Kraemer, A.
    Roesler, W.
    Haenel, M.
    Einsele, H.
    Baldus, C. D.
    Trappe, R. U.
    Stoelzel, F.
    Middeke, J. M.
    Roellig, C.
    Taube, F.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    BONE MARROW TRANSPLANTATION, 2017, 52 : S81 - S81
  • [5] The value of allogeneic stem cell transplantation in patients with intermediate risk (ELN) Acute Myeloid Leukemia with no FLT3-ITD, no NPM1 mutations and no CEBPA double mutations
    Heidrich, K.
    Thiede, C.
    Schaefer-Eckart, K.
    Schmitz, N.
    Aulitzky, W. E.
    Kraemer, A.
    Roesler, W.
    Haenel, M.
    Einsele, H.
    Baldus, C. D.
    Trappe, R. U.
    Stoelzel, F.
    Middeke, J. M.
    Roellig, C.
    Taube, F.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 28 - 28
  • [6] Allogeneic hematopoietic cell transplantation in intermediate risk acute myeloid leukemia negative for FLT3-ITD, NPM1- or biallelic CEBPA mutations
    Heidrich, K.
    Thiede, C.
    Schaefer-Eckart, K.
    Schmitz, N.
    Aulitzky, W. E.
    Kraemer, A.
    Roesler, W.
    Haenel, M.
    Einsele, H.
    Baldus, C. D.
    Trappe, R. U.
    Stoelzel, F.
    Middeke, J. M.
    Roellig, C.
    Taube, F.
    Kramer, M.
    Serve, H.
    Berdel, W. E.
    Ehninger, G.
    Bornhaeuser, M.
    Schetelig, J.
    ANNALS OF ONCOLOGY, 2017, 28 (11) : 2793 - 2798
  • [7] The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation
    Su, Long
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (01) : 64 - 64
  • [8] The Impact of DNMT3A/FLT3-ITD/NPM1 on Patients with Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation Reply
    Chahardouli, Bahram
    Mohammadi, Saeed
    Nikbakht, Mohsen
    Rostami, Shahrbano
    TURKISH JOURNAL OF HEMATOLOGY, 2019, 36 (01) : 65 - 66
  • [9] Double CEBPA mutations are prognostically favorable in non-M3 acute myeloid leukemia patients with wild-type NPM1 and FLT3-ITD
    Wen, Xiang-Mei
    Lin, Jiang
    Yang, Jing
    Yao, Dong-Ming
    Deng, Zhao-Qun
    Tang, Chun-Yan
    Xiao, Gao-Fei
    Yang, Lei
    Ma, Ji-Chun
    Hu, Jia-Bo
    Qian, Wei
    Qian, Jun
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2014, 7 (10): : 6832 - U1042
  • [10] CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk
    Park, Sang Hyuk
    Chi, Hyun-Sook
    Cho, Young-Uk
    Jang, Seongsoo
    Park, Chan-Jeoung
    LEUKEMIA RESEARCH, 2013, 37 (11) : 1488 - 1494
123